Sci Rep:亚洲前列腺癌患者中周围血栓栓塞性血管疾病与雄激素阻断治疗相关性分析

2019-10-12 AlexYang MedSci原创

最近,有研究人员在前列腺癌(PCa)患者中调查了血栓栓塞的血管疾病在雄激素阻断治疗(ADT)后的风险情况。研究包括了24464名在2000-2008年新诊断为PCa的患者,且是通过纵向医疗保险数据库获得数据。所有的的PCa患者分成了2组:ADT组和非ADT组。ADT治疗的患者再分成手术去势组,化学去势组和单独抗雄激素组。研究人员通过依赖时间变量的多重Cox比例风险回归评估了肺栓塞(PE)、外周动脉

最近,有研究人员在前列腺癌(PCa)患者中调查了血栓栓塞的血管疾病在雄激素阻断治疗(ADT)后的风险情况。

研究包括了24464名在2000-2008年新诊断为PCa的患者,且是通过纵向医疗保险数据库获得数据。所有的的PCa患者分成了2组:ADT组和非ADT组。ADT治疗的患者再分成手术去势组,化学去势组和单独抗雄激素组。研究人员通过依赖时间变量的多重Cox比例风险回归评估了肺栓塞(PE)、外周动脉闭塞症(PAOD)和深静脉血栓形成(DVT)的风险。在12年的跟踪调查期间,ADT组和非ADT组中每1000人DVT的发生率分别为2.87和1.62;PE的发生率分别为1.00和0.52;PAOD的发生率分别为1.03和0.70。另外,与对应的ADT未接受患者相比,DVT和PE的风险在接受组合雄激素阻断(CAB)的患者中显著增加。在调整了潜在的风险因子后,接受CAB治疗的PCa患者具有最高的PE风险(HR=3.11),之后是DVT风险(HR=2.53)。DVT风险在整个化学去势中提高。然而,高PE风险在接受不大于720天治疗的患者中也存在。研究人员并未发现ADT和PAOD风险的相关性。

最后,研究人员指出,PE和DVT的风险在接受CAB治疗的亚洲PCa患者中较高,而PAOD风险与这些治疗没有关系。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837734, encodeId=f000183e734ec, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 17 00:00:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710200, encodeId=a2661e1020018, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Dec 25 12:00:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641283, encodeId=e0771641283ac, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat May 09 21:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385166, encodeId=bff313851665b, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498642, encodeId=573514986429b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523631, encodeId=6be31523631b8, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040565, encodeId=225b1040565a9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Oct 12 21:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837734, encodeId=f000183e734ec, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 17 00:00:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710200, encodeId=a2661e1020018, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Dec 25 12:00:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641283, encodeId=e0771641283ac, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat May 09 21:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385166, encodeId=bff313851665b, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498642, encodeId=573514986429b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523631, encodeId=6be31523631b8, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040565, encodeId=225b1040565a9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Oct 12 21:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837734, encodeId=f000183e734ec, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 17 00:00:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710200, encodeId=a2661e1020018, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Dec 25 12:00:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641283, encodeId=e0771641283ac, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat May 09 21:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385166, encodeId=bff313851665b, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498642, encodeId=573514986429b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523631, encodeId=6be31523631b8, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040565, encodeId=225b1040565a9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Oct 12 21:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837734, encodeId=f000183e734ec, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 17 00:00:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710200, encodeId=a2661e1020018, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Dec 25 12:00:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641283, encodeId=e0771641283ac, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat May 09 21:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385166, encodeId=bff313851665b, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498642, encodeId=573514986429b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523631, encodeId=6be31523631b8, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040565, encodeId=225b1040565a9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Oct 12 21:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837734, encodeId=f000183e734ec, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 17 00:00:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710200, encodeId=a2661e1020018, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Dec 25 12:00:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641283, encodeId=e0771641283ac, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat May 09 21:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385166, encodeId=bff313851665b, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498642, encodeId=573514986429b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523631, encodeId=6be31523631b8, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040565, encodeId=225b1040565a9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Oct 12 21:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1837734, encodeId=f000183e734ec, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 17 00:00:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710200, encodeId=a2661e1020018, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Dec 25 12:00:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641283, encodeId=e0771641283ac, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat May 09 21:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385166, encodeId=bff313851665b, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498642, encodeId=573514986429b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523631, encodeId=6be31523631b8, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040565, encodeId=225b1040565a9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Oct 12 21:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1837734, encodeId=f000183e734ec, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 17 00:00:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710200, encodeId=a2661e1020018, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Dec 25 12:00:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641283, encodeId=e0771641283ac, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat May 09 21:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385166, encodeId=bff313851665b, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498642, encodeId=573514986429b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523631, encodeId=6be31523631b8, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 14 09:00:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040565, encodeId=225b1040565a9, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Oct 12 21:00:00 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2019-10-12 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Nat Med:全基因组种系与前列腺癌表观遗传背景相关

肿瘤的发生可以由种系、环境和随机因素诱发。但这些因素是怎样互作产生肿瘤的分子表型的仍旧未知。最近,有研究人员在589个局部前列腺肿瘤中量化了种系多样性对体细胞表观基因组的影响。研究发现,倾向性风险位点影响了肿瘤的表观基因组,揭示了癌症易感性的机制。研究人员总共见顶了1178个位点与肿瘤组织中甲基化的改变有关,而不是非恶性肿瘤组织。这些肿瘤甲基化数量性状位点能够影响染色质结构以及RNA和蛋白的丰度。

Sci Rep:精液中的miRNAs可以作为前列腺癌诊断的非侵入性生物标记

尽管对前列腺组织是特异性的,血清前列腺特异性抗原(PSA)筛选经常导致前列腺癌的过度诊断和许多不必要的良性疾病活检,因此需要进一步的改善。最近,有研究人员对PSA水平适度提高的男性的精液的miRNAs表达水平进行了分析,从而评估其作为非侵入性生物标记来对PCa进行诊断和预后的应用价值。研究人员发现,高通量分析表明了PCa患者中miRNA表达模式与健康个体(HCt)相比发生了改变。研究人员考虑了输精

Eur Urol:前列腺癌发生率和死亡率全球模式分析

之前的研究报道了前列腺癌比例和趋势发生了明显的变化,主要是由于检测、治疗方法和潜在的遗传易感性差异。最近,有研究人员通过更新的发生率和死亡率数据评估了世界范围内前列腺癌的发生率和死亡率情况。研究发现,评估的最高发生率在澳大利亚和新西兰、北美、西欧和北欧以及加勒比地区,发生率最低的在中南亚、北非、东南亚和东亚。评估的死亡率最高在加勒比地区(包括巴巴多斯、特立尼达、多巴哥和古巴)、南非、前苏联部分地区

Sci Rep:前列腺癌细胞中AR无差异抗雄激素抗性驱使因子分析

二代抗雄激素类药物抑制雄激素受体(AR)是转移去势抵抗性前列腺癌(mCRPC)的标准治疗方法,但是不可避免的会导致抗性的产生。自从高效AR信号抑制剂的使用,大于20%的mCRPC的患者发展为不依赖AR抗性机制疾病。最近,有研究人员开发了2个抗雄激素药物和不依赖AR活性的去势抵抗性前列腺癌细胞模型,尽管模型中AR表达强烈(AR无差异)。这些模型对所有当今的AR信号抑制剂存在抗性。研究发现,这2个细胞

Sci Rep:病灶间的异质性挑战了分子分型在原发性前列腺癌中的临床使用

前列腺癌是高度异质性的疾病,并且在起始诊断时往往具有典型的多个不同的癌症病灶。前列腺癌的分子分型能够游离的辅助精准的诊断和治疗。在癌症基因组数据库(TCGA)中公开了一个很有前景的分型工具,并基于每个患者的癌症样本成功的对74%的原发性前列腺癌分型,共分成了7组。最近,有研究人员探索了该分型工具的临床使用情况,他们在一个多病灶的背景下对该分型工具进行了测试。研究人员共分析了来自于39名患者的85个

Nat Commun:PTEN-ARID4B-PI3K途径鉴定了PTEN缺陷前列腺癌对ARID4B的依赖性

在前列腺癌中,PTEN经常发生变异。PTEN的肿瘤抑制子功能归结于其脂肪磷酸化活性且能够拮抗PI3K的作用。最近,有研究人员报道了PTEN-ARID4B-PI3K途径,其中PTEN能够抑制ARID4B的表达,而ARID4B是PI3K亚单元基因PIK3CA和PIK3R2的转录激活因子,且亚单元基因PIK3CA和PIK3R2对PI3K/AKT途径的激活是非常关键的。ARID4B和组蛋白H1结合到PIK